drugset

drugset / Trial / NCT06408311

Safety of ENC-201-CED ENCRT

NCT06408311 ↗

Phase 1 Active not recruiting 10 enrolled Encellin resCON Research · collab

NaSingle-groupOpen-labelDevice feasibility

Summary

The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.

Timeline

Start: 2024-05-01
Primary completion: 2026-07-31
Completion: 2026-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENC-201-CED hPI	Cell therapy	—	Subcutaneous

Indications